Consortium for the study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Consortium – Pittsburgh Clinical Center

慢性胰腺炎、糖尿病和胰腺癌研究联盟 — 匹兹堡临床中心

• 批准号: 10888715
• 负责人: Randall Brand
• 金额: $ 13.5万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-28 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10888715
• 关键词: Ancillary Study; Area; Authorization documentation; Bioinformatics; Biological; Biological Markers; Biometry; Clinical; Collaborations; Diabetes Mellitus; Effectiveness; Endocrinology; Ensure; Epidemiology; Funding; Genetic; Image; Infrastructure; Leadership; Malignant neoplasm of pancreas; Pain; Pancreatic Diseases; Pancreatitis; Patients; Phenotype; Physiology; Publications; Recurrence; Research; Research Infrastructure; Research Personnel; Resources; Risk; Sampling; Screening for cancer; Universities; Urine; acute pancreatitis; authority; chronic pancreatitis; clinical center; clinical infrastructure; clinical translation; cohort; data exchange; data management; design; disorder subtype; member; multidisciplinary; organizational structure; programs; randomized, clinical trials; success; working group

Abstract. Consortium for the Study of Pancreatitis: Pittsburgh Clinical Center. The Consortium for the Study of Pancreatitis: Pittsburgh Clinical Center (PCC) is a multidisciplinary clinical- translational program at the University of Pittsburgh and UPMC. The PCC is one of the 10 founding members of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC). The organizational structure of PCC allows comprehensive epidemiological, clinical and biological characterization of patients with pancreatic disorders in order to conduct clinical, translational and mechanistic studies of recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP) and their sequelae such as Type 3c diabetes and pancreatic cancer. The PCC is highly integrated at all levels of the CPDPC, including leadership, participation in Committees and Working Groups, contribution to primary cohorts, several ancillary studies and publications. PCC has been effective in utilizing the CPDPC infrastructure and resources for high-quality scientific projects. In the next five years of funding, the PCC is committed to completing ascertainment of the primary CPDPC cohorts, execution of the currently approved ancillary studies, and participating in new projects. We will also propose concepts for three new ancillary studies that will utilize the infrastructure and resources of the CPDPC. Our specific aims are: Aim 1. Contribute to completing the acquisition of CPDPC’s primary cohorts and ongoing ancillary studies. Aim 2. We will propose and support new ancillary projects to use the infrastructure created with the primary cohorts and ongoing ancillary studies. As part of Aim 2, we propose concepts for three ancillary projects, to – i) Develop a Chronic Pancreatitis Risk Score (CPRS) for use in randomized clinical trials of CP, ii) Identify Urine Biomarkers of Pain (UBP) for mechanism-based phenotyping of CP pain, and iii) Use a genotying approach to enrich the New Onset Diabetes (NOD) cohort. Our existing and well-established, efficient and effective clinical and research infrastructure for patient accrual, sample processing, data management and transfer, and analysis will support the program. The rich clinical volume, diverse investigator expertise in all critical areas such as pancreatology, epidemiology, early detection of cancer, genetics, physiology, imaging, endocrinology, biostatistics and bioinformatics, and all relevant disease subtypes, administrative authority in clinical and research areas ensure continued success. Our track record of leadership, strong collaborations and working relationships within the CPDPC and other collaborative networks will also ensure continued success and effectiveness of the CPDPC.

抽象。 胰腺炎研究联盟：匹兹堡临床中心。 胰腺炎研究联盟：匹兹堡临床中心（PCC）是一个多学科的临床- 匹兹堡大学和UPMC的翻译项目。PCC是10个创始成员之一 慢性胰腺炎、糖尿病和胰腺癌研究联合会（CPDPC）。的 PCC的组织结构允许全面的流行病学、临床和生物学表征 对胰腺疾病患者进行临床、转化和机制研究， 复发性急性胰腺炎（RAP）和慢性胰腺炎（CP）及其后遗症，如3c型糖尿病 和胰腺癌政治协商委员会在CPDPC的所有级别都高度一体化，包括领导层， 参加委员会和工作组，为主要队列、若干辅助研究和 出版物。PCC有效地利用CPDPC的基础设施和资源， 科学项目。在未来五年的资金，PCC致力于完成确定 主要CPDPC队列，执行当前批准的辅助研究，并参与新的 项目我们还将提出三个新的辅助研究的概念，这些研究将利用基础设施， CPDPC的资源。我们的具体目标是：目标1。协助完成对CPDPC的收购 主要队列和正在进行的辅助研究。目标2.我们会建议和支持新的配套项目， 使用主要队列和正在进行的辅助研究创建的基础设施。作为目标2的一部分，我们 提出三个辅助项目的概念，i）制定慢性胰腺炎风险评分（CPRS）， 在CP的随机临床试验中，ii）鉴定用于基于机制的疼痛的尿生物标志物（UBP）， CP疼痛的表型，和iii）使用基因分型方法来丰富新发糖尿病（NOD）队列。 我们现有的和完善的，高效和有效的临床和研究基础设施，为病人的增加， 样品处理、数据管理和传输以及分析将支持该方案。丰富的临床 在所有关键领域（如胰腺病学、流行病学、早期发现）拥有大量、多样化的研究者专业知识 癌症，遗传学，生理学，成像，内分泌学，生物统计学和生物信息学，以及所有相关的 疾病亚型、临床和研究领域的行政管理权威确保了持续的成功。我们的赛道 领导记录，在CPDPC和其他合作组织内的强有力的合作和工作关系 网络也将确保CPDPC的持续成功和有效性。

项目成果

Predicting the Prognosis of Acute Pancreatitis.

预测急性胰腺炎的预后。

• DOI: 10.7326/m16-1581
• 发表时间: 2016
• 期刊: Annals of internal medicine
• 影响因子: 39.2
• 作者: Forsmark,ChrisE;Yadav,Dhiraj
• 通讯作者: Yadav,Dhiraj

Pancreatic Enzyme Replacement Therapy in Patients with Non-pancreatic Digestive Conditions: A Nationwide Claims Analysis.

非胰腺消化疾病患者的胰腺酶替代疗法：全国索赔分析。

• DOI: 10.1007/s10620-022-07750-y
• 发表时间: 2023
• 期刊: Digestive diseases and sciences
• 影响因子: 3.1
• 作者: Phillips,AnnaEvans;Tang,Gong;Wang,Xianling;Forsmark,ChristopherE;Yadav,Dhiraj
• 通讯作者: Yadav,Dhiraj

Chronic pancreatitis: An international draft consensus proposal for a new mechanistic definition.

• DOI: 10.1016/j.pan.2016.02.001
• 发表时间: 2016-03
• 期刊: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
• 作者: Whitcomb DC;Frulloni L;Garg P;Greer JB;Schneider A;Yadav D;Shimosegawa T
• 通讯作者: Shimosegawa T

Managing chronic pancreatitis: the view from medical pancreatology.

• DOI: 10.1038/s41395-018-0066-z
• 发表时间: 2018-08
• 期刊: The American journal of gastroenterology
• 作者: Yadav D;Slivka A
• 通讯作者: Slivka A

The histopathology of SPINK1-associated chronic pancreatitis.

• DOI: 10.1016/j.pan.2020.10.030
• 发表时间: 2020-12
• 期刊: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
• 作者: Jones TE;Bellin MD;Yadav D;Freeman ML;Schwarzenberg SJ;Slivka A;Chennat JS;Beilman GJ;Chinnakotla S;Pruett TL;Kirchner V;Humar A;Wijkstrom M;Zureikat AH;Nikiforova MN;Wald AI;Whitcomb DC;Singhi AD
• 通讯作者: Singhi AD